<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256698</url>
  </required_header>
  <id_info>
    <org_study_id>D6997L00002</org_study_id>
    <secondary_id>9238SW/0001</secondary_id>
    <secondary_id>FACT</secondary_id>
    <nct_id>NCT00256698</nct_id>
  </id_info>
  <brief_title>Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy</brief_title>
  <acronym>FACT</acronym>
  <official_title>FACT: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy; an Open Randomized, Comparative, Phase III Multicentre Study in Postmenopausal Women With Hormone Receptor Positive Breast Cancer in First Relapse After Primary Treatment of Localized Tumor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of anastrozole monotherapy versus
      maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared
      with in treatment of hormone receptor positive women with first relapse of breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>RECIST assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
    <description>RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve &quot;respond&quot;, stay the same &quot;stable&quot;or worsen &quot;progression&quot; during treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Evaluable Participants With Objective Response Rate (ORR)</measure>
    <time_frame>RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
    <description>No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (&gt;= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Clinical Benefit Rate (CBR) Responders</measure>
    <time_frame>RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
    <description>No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD&gt;=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
    <description>Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Clinical Benefit (DoCB)</measure>
    <time_frame>RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
    <description>Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>From randomisation until data cut-off on 30th April 2009</time_frame>
    <description>Time from randomisation until the date of discontinuation of randomised treatment for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>All deaths occurring between randomisation and data cut-off on 30th April 2009 are included.</time_frame>
    <description>Overall survival is equivalent to time to death. Time from randomisation until the date of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anastrozole + Fulvestrant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>intramuscular injection 250 mg loading dose (LD) regimen</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Faslodex</other_name>
    <other_name>ZD9238</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg oral tablet</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Arimidex</other_name>
    <other_name>ZD1033</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent, postmenopausal females, histological or cytological confirmed
             oestrogene and/or progesterone (PgR) receptor positive breast cancer, local recurrence
             or metastasis

        Exclusion Criteria:

          -  Previous systemic endocrine therapy for advanced or recurrent disease; prior
             fulvestrant therapy

          -  Premenopausal women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Henriksson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingston</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ontario</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hameenlinna</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Chaussee Saint Victor</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perigueux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Cyr Sur Louire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gifhorn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grosshadern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ziwicken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fabriano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taormina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Treviglio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ilesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porsgrunn</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Troms</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cascais</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Maria da Feira</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlskrona</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kristianstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Link'ping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>M'lndal</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norrk'ping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skelleftea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skovde</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunderbyn</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>V'rnamo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>V'stervik</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edirne</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Iceland</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2005</study_first_submitted>
  <study_first_submitted_qc>November 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2005</study_first_posted>
  <results_first_submitted>April 29, 2010</results_first_submitted>
  <results_first_submitted_qc>January 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2011</results_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone</keyword>
  <keyword>receptor</keyword>
  <keyword>positive</keyword>
  <keyword>breast</keyword>
  <keyword>cancer</keyword>
  <keyword>first</keyword>
  <keyword>relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>258 patients were randomised to Fulvestrant + Anastrozole and 256 patients were randomised to Anastrozole. In each treatment group, there were 2 patients who did not receive any trial therapy and so have been excluded from the safety summaries.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fulvestrant + Anastrozole</title>
          <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
        </group>
        <group group_id="P2">
          <title>Anastrozole</title>
          <description>Anastrozole 1 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="256"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>still ongoing at data cut-off</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrawn due to osteoporosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prematurely Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fulvestrant + Anastrozole</title>
          <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
        </group>
        <group group_id="B2">
          <title>Anastrozole</title>
          <description>Anastrozole 1 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="258"/>
            <count group_id="B2" value="256"/>
            <count group_id="B3" value="514"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="9.6"/>
                    <measurement group_id="B2" value="63.4" spread="10.3"/>
                    <measurement group_id="B3" value="64.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression (TTP)</title>
        <description>RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve &quot;respond&quot;, stay the same &quot;stable&quot;or worsen &quot;progression&quot; during treatments.</description>
        <time_frame>RECIST assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole 1 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve &quot;respond&quot;, stay the same &quot;stable&quot;or worsen &quot;progression&quot; during treatments.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="0" upper_limit="49.31"/>
                    <measurement group_id="O2" value="10.2" lower_limit="0" upper_limit="54.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Evaluable Participants With Objective Response Rate (ORR)</title>
        <description>No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (&gt;= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)</description>
        <time_frame>RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole 1 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Evaluable Participants With Objective Response Rate (ORR)</title>
          <description>No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (&gt;= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)</description>
          <units>Percentage of evaluable participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Clinical Benefit Rate (CBR) Responders</title>
        <description>No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD&gt;=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)</description>
        <time_frame>RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole 1 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Clinical Benefit Rate (CBR) Responders</title>
          <description>No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD&gt;=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                    <measurement group_id="O2" value="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR)</title>
        <description>Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders</description>
        <time_frame>RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole 1 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR)</title>
          <description>Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="5.55" upper_limit="46.95"/>
                    <measurement group_id="O2" value="18.2" lower_limit="7.20" upper_limit="49.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Clinical Benefit (DoCB)</title>
        <description>Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders</description>
        <time_frame>RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole 1 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Clinical Benefit (DoCB)</title>
          <description>Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="1.64" upper_limit="46.95"/>
                    <measurement group_id="O2" value="18.1" lower_limit="5.19" upper_limit="54.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (TTF)</title>
        <description>Time from randomisation until the date of discontinuation of randomised treatment for any reason</description>
        <time_frame>From randomisation until data cut-off on 30th April 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole 1 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (TTF)</title>
          <description>Time from randomisation until the date of discontinuation of randomised treatment for any reason</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="0" upper_limit="46.95"/>
                    <measurement group_id="O2" value="11.4" lower_limit="0" upper_limit="54.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is equivalent to time to death. Time from randomisation until the date of death</description>
        <time_frame>All deaths occurring between randomisation and data cut-off on 30th April 2009 are included.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole 1 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is equivalent to time to death. Time from randomisation until the date of death</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" lower_limit="0.07" upper_limit="61.86"/>
                    <measurement group_id="O2" value="38.2" lower_limit="0.13" upper_limit="60.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fulvestrant + Anastrozole</title>
          <description>Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg</description>
        </group>
        <group group_id="E2">
          <title>Anastrozole</title>
          <description>Anastrozole 1 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Foot Amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bronchpneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Fractured Sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Metastases To Meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Intracranial Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cerebellar Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pleuritic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous Stasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that they cannot disclose or publish any information to do with the trial without consent from AstraZeneca</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

